艾迪注射液联合培美曲塞对非小细胞肺癌患者T淋巴细胞亚群的影响

Effects of Aidi Injection Combined with Pemetrexed on T Lymphocyte Subsets in Patients with NSCLC

目的探讨艾迪注射液联合培美曲塞对非小细胞肺癌(NSCLC)患者T淋巴细胞亚群的影响。方法选取2016年3月-2018年2月我院接受培美曲塞联合顺铂治疗的NSCLC患者128例为研究对象。按照治疗方案的不同平均分为对照组和观察组。对照组采用培美曲塞+顺铂化疗;观察组在对照组的基础上加用艾迪注射液;连续治疗2个周期后,评价两组患者的临床疗效、T淋巴细胞亚群及不良反应发生情况。结果观察组患者临床总有效率高于对照组,但差异无统计学意义(P>0.05)。与治疗前相比,两组患者外周血CD3^+、CD4^+、CD19^+、CD16^+CD56^+水平以及CD4^+/CD8^+比值均有所升高。其中,对照组患者CD8^+水平显著低于治疗前(P>0.05),CD19^+水平显著高于治疗前(P<0.05);观察组患者CD4^+、CD8^+、CD16^+CD56^+、CD19^+水平均显著高于治疗前,且明显高于对照组(P<0.05)。两组患者的主要不良反应均为血液系统毒性,以白细胞减少最为常见。观察组患者白细胞减少、血小板减少、消化道反应的发生率均显著低于对照组(P<0.05);红细胞减少、神经毒性、肝功能及肾功能损伤的发生率与对照组无显著差异(P>0.05)。结论培美曲塞联合艾迪注射液可显著改善患者的免疫功能,对临床疗效的改善具有积极意义。

Objective To investigate the effects of Aidi injection combined with pemetrexed on T lymphocyte subsets in patients with NSCLC.Methods A total of 128 patients with NSCLC treated in our hospital between March 2016 and February 2018 were selected as the study subjects.Patients were divided into control group and obsenvation group according to different treatment schemes.The control group was treated with pemetrexed and cisplatin,while the observation group was treated with Aidi injection on the basis of treatment of control group.After two cycles of continuous treatment,the clinical efficacy,T lymphocyte subsets and adverse reactions of the two groups were evaluated.Results After treatment,the total effective rate of obsenvation group was higher than that of the control group,but the difference showed no statistical significance(P>0.05).Compared with before treatment,the levels of CD3^+,CD4^+,CD16^+CD56^+,CD19^+and the CD4^+/CD8^+were increased in the two groups after treatment.The CD8^+level decreased in the control group,but there was no significant difference(P>0.05).The CD19^+level increased significantly in the control group after treatment(P<0.05).The levels of CD4^+,CD8^+,CD16^+CD56^+,CD19^+in the observation group after treatment were higher than before treatment(P<0.05).They were also higher than those of the control group after treatment(P<0.05).The main adverse reactions of the two groups were hematological reactions,and leukopenia was the most common adverse reaction.The incidences of leukopenia,thrombocytopenia and digestive system reaction in the observation group was less than in the control group(P<0.05).There was no significant difference in the incidences of erythrocytopenia,neurotoxicity,liver function and renal function damage between the two groups(P>0.05).Conclusion Pemetrexed combined with Aidi injection could improve the immune function of patients.It is beneficial to improve the clinical efficacy.